Applied Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:2UV Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
04 Mar 25	Sell€187	Constantine Chinoporos	Individual	447	€0.42
04 Mar 25	Sell€6,059	Les Funtleyder	Individual	14,502	€0.42
04 Mar 25	Sell€4,331	Riccardo Perfetti	Individual	10,366	€0.42
06 Feb 25	Sell€13,493	Les Funtleyder	Individual	22,950	€0.59
06 Feb 25	Sell€50,607	Riccardo Perfetti	Individual	86,078	€0.59
06 Feb 25	Sell€16,530	Constantine Chinoporos	Individual	28,117	€0.59
22 Aug 24	Sell€119,047	Riccardo Perfetti	Individual	22,681	€5.25
22 Aug 24	Sell€71,016	Les Funtleyder	Individual	13,530	€5.25
14 Aug 24	Sell€4,273,357	Shoshana Shendelman	Individual	777,014	€5.60
06 Jun 24	Sell€87,354	Riccardo Perfetti	Individual	22,003	€3.97
06 Jun 24	Sell€67,412	Les Funtleyder	Individual	16,980	€3.97
06 Jun 24	Sell€245,331	Shoshana Shendelman	Individual	61,795	€3.97
05 Jun 24	Sell€1,166,480	Alexandria Venture Investments, LLC	Company	300,000	€3.90

Insider Trading Volume

Insider Buying: 2UV insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 2UV?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	1,580,491	1.12%
Individual Insiders	2,437,463	1.72%
VC/PE Firms	7,799,687	5.51%
Hedge Funds	11,500,000	8.12%
General Public	19,201,054	13.6%
Institutions	99,056,831	70%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.9%.

Top Shareholders

Top 25 shareholders own 79.75% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
11%	T. Rowe Price Group, Inc.	15,612,586	€4.9m	49.9%	no data
8.12%	Vestal Point Capital, LP	11,500,000	€3.6m	0%	0.31%
7.97%	Propel Bio Management, LLC	11,285,420	€3.5m	66%	4.83%
6.75%	BlackRock, Inc.	9,551,302	€3.0m	2.75%	no data
5.51%	Knoll Capital Management	7,799,687	€2.4m	34.5%	2.3%
4.28%	Alexandria Venture Investments, LLC	6,059,054	€1.9m	0%	100.0%
4.16%	The Vanguard Group, Inc.	5,889,193	€1.8m	6.15%	no data
3.93%	VR Adviser, LLC	5,567,709	€1.7m	-44.3%	0.15%
3.3%	Schonfeld Strategic Advisors LLC	4,676,097	€1.5m	-46.6%	0.01%
3.17%	Simplify Asset Management Inc.	4,487,505	€1.4m	59.3%	0.07%
3.15%	Deutsche Asset & Wealth Management	4,466,585	€1.4m	-0.03%	no data
2.19%	Alyeska Investment Group, L.P.	3,107,497	€972.7k	14.8%	no data
2.03%	Morgan Stanley, Investment Banking and Brokerage Investments	2,869,901	€898.3k	-67.4%	no data
1.72%	Tang Capital Management, LLC	2,428,169	€760.1k	0%	0.04%
1.52%	Geode Capital Management, LLC	2,151,392	€673.4k	3.23%	no data
1.47%	Rock Springs Capital Management LP	2,074,891	€649.5k	8.23%	0.04%
1.42%	Franklin Resources, Inc.	2,003,338	€627.1k	0%	no data
1.39%	Adage Capital Management, L.P.	1,961,629	€614.0k	0%	no data
1.38%	State Street Global Advisors, Inc.	1,950,909	€610.7k	-5.59%	no data
1.37%	Qube Research & Technologies Ltd	1,939,004	€606.9k	-0.59%	no data
1.05%	Sycamore Family LLC	1,492,094	€467.0k	0%	no data
0.92%	Marshall Wace LLP	1,307,381	€409.2k	0%	no data
0.68%	Two Sigma Investments, LP	960,587	€300.7k	227%	no data
0.64%	Richard Kayne	901,907	€282.3k	0%	no data
0.61%	Perceptive Advisors LLC	860,000	€269.2k	0%	0.01%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/03 10:29
End of Day Share Price	2025/06/03 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Applied Therapeutics, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Carter Gould	Barclays
Paul Choi	Goldman Sachs